Skip to main content
OpenTrials
Completed

NCT Number: NCT07053163

Low Dose of Norepinephrine Within 24-Hour Mortality in Traumatic Patient With Hemorrhagic Shock

The aim of the work is to evaluate role of low dose of nor epinephrine administration in the early 24-hour period among traumatic patients and hemorrhagic shock. The primary outcome: evaluate mortality at first 24 hour. The secondary outcome : measure total fluid intake, observe renal functions and Hemodynamic changes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tanta University

Tanta, Gharbia Governorate, Egypt

About this study

Uncontrolled hemorrhage remains the leading cause of preventable death among patients with trauma, despite considerable improvements in trauma care Trauma- induced hemorrhage and hypovolemia can trigger an increase neurohormonal response and hypotension is not explained by hypovolemia alone but is associated with sympathy inhibitory-induced vasodilation. Trauma was defined as any exposure to nonpenetrating or penetrating kinetic energy, collision, or deceleration, Patients were alive on admission with hemorrhagic shock, defined by prehospital or admission mean arterial blood pressure less than 65 mm Hg. Management of shock after trauma remains a clinical challenge, in particular if associated with active hemorrhage and vasopressors are part of the recommended therapeutic routinely used by clinicians in Europe . Historically, the importance of permissive hypotension and the restriction of crystalloid fluid volume before hemorrhage control has been confirmed with good outcomes in patients with penetrating trauma.

Vasopressors mimic the initial response to blood loss; improve venous return, coronary perfusion, and myocardial contractility. Generally, vasopressors are considered to have a negative impact on patient outcome in the management of hemorrhagic Shock, and the predominant strategy is based on permissive hypotension and low volume resuscitation.

vasopressor use in hemorrhagic Shock in humans. The use of vasopressors, such as norepinephrine for the hemodynamic management of hemorrhagic shock, may be considered in the early phase of resuscitation and is a common practice among several prehospital and hospital emergency teams in Europe. Where any surgical or interventional radiographic procedures for the immediate control of bleeding and early activation of massive transfusion protocol are always not available, the effects vasopressor administration for severe hemorrhagic shock following trauma is used to restore arterial pressure in hemorrhagic shock. Norepinephrine is a sympathomimetic agent with predominantly vasoconstrictive effects. Norepinephrine exerts both arterial and venous α-adrenergic stimulation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 -65 Years old.
  • Multiple organ injury.
  • Recent trauma within 1st 24 hour.
  • Mean arterial blood pressure <65 mmHg

Exclusion criteria

  • Cardiac arrest at admission.
  • Old trauma more than 24 hour.
  • Severe brain or spinal injury (because of different target blood pressures).
  • Death due to haemostatic failure within 6 hours of admission

Treatment and study plan

Crystalloid and blood as resuscitation

Drug

Patients receive crystalloid and blood as resuscitation

crystalloid, blood and low dose of norepinephrine

Drug

Group 2: receive crystalloid, blood and low dose of norepinephrine

Primary outcomes

  1. Mortality

    Time frame: at first 24 hour

Secondary outcomes

  1. total fluid intake

    Time frame: at first 24 hour

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Role of Low Dose of Norepinephrine Administration Within 24-Hour Mortality in Traumatic Patient With Hemorrhagic Shock

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 8, 2025
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.